TOPIC 420 INTEGRATED PLATFORM FOR IN-DEPTH SINGLE-CELL PROTEOMICSPERIOD OF PERFORMANCE SEPTEMBER 13, 2021-JUNE 12, 2022FY21 PHASE I SBIR
TOPIC 420 深度单细胞蛋白质组学综合平台 性能周期 2021年9月13日-2022年6月12日 FY21 第一期 SBIR
基本信息
- 批准号:10610297
- 负责人:
- 金额:$ 5.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-13 至 2022-06-21
- 项目状态:已结题
- 来源:
- 关键词:AutomationCancer DiagnosticsCellsComputer softwareCustomDevelopmentHela CellsImpairmentMalignant NeoplasmsManualsMeasurementNeoplasm Circulating CellsPerformancePhasePositioning AttributePreparationProteinsProteomeRecoveryReproducibilityRoboticsSamplingSmall Business Innovation Research GrantStructureSystemTissuesanticancer researchbiological systemscostdata qualityinstrumentliquid chromatography mass spectrometrynanolitrenanolitre scaleopen sourceprotein expressionsingle cell proteinstargeted treatmenttumor heterogeneity
项目摘要
Proteins are key functional and structure components of biological systems including cancers, and are the primary targets of therapeutics. The ability to directly profile protein expression for cancer research and diagnostics has been impaired by the large amounts of tissue required to perform a measurement. These bulk analyses obscure important tumor heterogeneity and are unable to profile rare but important cells such as circulating tumor cells. We have recently developed a nanoliter-scale sample preparation platform termed nanoPOTS. When combined with ultrasensitive analysis, nanoPOTS enables profiling of hundreds to >1000 proteins from single cells but currently involves several manual steps and multiple custom instruments that make it unsuitable for broad dissemination. We will develop an integrated robotic platform that accomplishes both nanoliter-scale sample preparation and nanoliter-scale interfacing with LC/MS analysis. We will also evaluate alternative ‘nanowell’ substrate materials for nanoPOTS processing and a simplified one-step processing workflow. The system will be characterized in terms of achievable proteome coverage, reproducibility and throughput using single HeLa cells. Data quality will be assessed using open-source software. We expect to identify >800 proteins in single HeLa cells, positioning the system for full automation and increased measurement throughput during the subsequent phase of development.
蛋白质是包括癌症在内的生物系统的关键功能和结构组分,并且是治疗剂的主要靶标。由于进行测量所需的大量组织,直接分析癌症研究和诊断的蛋白质表达的能力受到损害。这些批量分析掩盖了重要的肿瘤异质性,并且无法分析罕见但重要的细胞,如循环肿瘤细胞。我们最近开发了一种称为nanoPOTS的纳升级样品制备平台。当与超灵敏度分析相结合时,nanoPOTS能够从单细胞中分析数百至>1000种蛋白质,但目前涉及几个手动步骤和多个定制仪器,使其不适合广泛传播。我们将开发一个集成的机器人平台,完成纳升规模的样品制备和纳升规模的LC/MS分析接口。我们还将评估用于nanoPOTS处理的替代“单细胞”衬底材料和简化的一步处理工作流程。该系统的特点是可实现的蛋白质组覆盖率,再现性和吞吐量使用单一的HeLa细胞。数据质量将使用开源软件进行评估。我们希望在单个HeLa细胞中识别超过800种蛋白质,使系统在后续开发阶段实现全自动化并提高测量通量。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
RYAN KELLY其他文献
RYAN KELLY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('RYAN KELLY', 18)}}的其他基金
SBIR PHASE II, TOPIC 420: INTEGRATED PLATFORM AND CONSUMABLES FOR ROBUST, SENSITIVE AND HIGH-THROUGHPUT SINGLE-CELL PROTEOMICS
SBIR 第二阶段,主题 420:用于稳健、灵敏和高通量单细胞蛋白质组学的集成平台和耗材
- 批准号:
10948319 - 财政年份:2023
- 资助金额:
$ 5.5万 - 项目类别:
相似海外基金
SBIR Phase I: Enrichment of Cancer DNA for Improved Cancer Diagnostics from Blood
SBIR 第一阶段:富集癌症 DNA 以改善血液癌症诊断
- 批准号:
2321908 - 财政年份:2023
- 资助金额:
$ 5.5万 - 项目类别:
Standard Grant
Smart cloud-based platform for lung cancer diagnostics validation
用于肺癌诊断验证的智能云平台
- 批准号:
10050405 - 财政年份:2023
- 资助金额:
$ 5.5万 - 项目类别:
Collaborative R&D
EAGER: Causal Analysis through Formal Reasoning and AI for Cancer Diagnostics
EAGER:通过形式推理和人工智能进行癌症诊断的因果分析
- 批准号:
2320050 - 财政年份:2023
- 资助金额:
$ 5.5万 - 项目类别:
Standard Grant
Microneedle Array Based Optical Biosensors for Minimally-Invasive Skin Cancer Diagnostics
基于微针阵列的光学生物传感器用于微创皮肤癌诊断
- 批准号:
2744608 - 财政年份:2022
- 资助金额:
$ 5.5万 - 项目类别:
Studentship
Quantitative and multiplexed immunolabeling for lung cancer diagnostics
用于肺癌诊断的定量和多重免疫标记
- 批准号:
567900-2022 - 财政年份:2022
- 资助金额:
$ 5.5万 - 项目类别:
Postdoctoral Fellowships
Early cancer diagnostics using evanescent wave Mid-IR spectroscopy
使用倏逝波中红外光谱进行早期癌症诊断
- 批准号:
2749522 - 财政年份:2022
- 资助金额:
$ 5.5万 - 项目类别:
Studentship
Quantitative and multiplexed immunolabeling for lung cancer diagnostics
用于肺癌诊断的定量和多重免疫标记
- 批准号:
580219-2022 - 财政年份:2022
- 资助金额:
$ 5.5万 - 项目类别:
Banting Postdoctoral Fellowships Tri-council
Multiplexed and quantitative immunolabelling for cancer diagnostics using gold-silver alloy nanoprobes
使用金银合金纳米探针进行癌症诊断的多重定量免疫标记
- 批准号:
571982-2022 - 财政年份:2022
- 资助金额:
$ 5.5万 - 项目类别:
Idea to Innovation
PreCisE: A Precision laser scalpel for Cancer diagnostics and Eradication
PreCisE:用于癌症诊断和根除的精密激光手术刀
- 批准号:
EP/V006185/1 - 财政年份:2021
- 资助金额:
$ 5.5万 - 项目类别:
Research Grant
Validation of epigenomic biomarkers for thyroid cancer diagnostics
用于甲状腺癌诊断的表观基因组生物标志物的验证
- 批准号:
10299473 - 财政年份:2021
- 资助金额:
$ 5.5万 - 项目类别: